Business Development Opportunities
Ion channels are becoming increasingly better validated as a drug target class, across a wide range of therapeutic areas. We are interested in applying our expertise in ion channel drug discovery in partnership with companies that share our interest in this underexploited target class.
We welcome potential partnership discussions on preclinical research alliances, including Xention’s existing projects in chronic pain/respiratory disease and autoimmune disease.
Please contact us at business-development@xention.com for more information